Related Experiment Video

Updated: May 20, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Radiotherapy plus chemotherapy in muscle-invasive bladder cancer

Carl D Atkins, Stephen H Wrzesinski

    The New England Journal of Medicine
    |July 27, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    Related Experiment Videos

    Last Updated: May 20, 2026

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
    11:02

    Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

    Published on: October 30, 2013

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
    08:43

    An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

    Published on: July 28, 2012

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Emerging therapeutic options for periorbital and orbital cutaneous basal and squamous cell carcinomas.

    Orbit (Amsterdam, Netherlands)·2022

    Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.

    Science immunology·2020

    Getting to the End Zone With Medicare for All.

    The Journal of ambulatory care management·2019

    Genetic profiles of plasmacytoid (BDCA-4 expressing) DC subtypes-clues to DC subtype function in vivo.

    Experimental hematology & oncology·2013

    Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy.

    Nature materials·2012

    Systemic therapy in hepatocellular carcinoma.

    Clinics in liver disease·2011

    Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis.

    The New England journal of medicine·2026

    Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

    The New England journal of medicine·2026

    Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.

    The New England journal of medicine·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us